Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
A legfontosabb adatok
- Ki végzi
- Abbott Medical Devices
- Hol
- Albany, Ann Arbor, Asheville, Atlanta, Aurora, Austin, Balitmore, Baltimore, Bay Shore, Birmingham, Boise, Bradenton, Buffalo, Charleston, Charlotte, Charlottesville, Chicago, Cincinnati, Clearwater, Cleveland, Dallas, Delray Beach, Detroit, Falls Church, Fresno, Gainesville, Hackensack, Houston, Indianapolis, Kansas City, Little Rock, Los Angeles, Manchester, Marietta, Memphis, Miami, Milwaukee, Minneapolis, Missoula, Morgantown, Nashville, New Brunswick, New York, Newark, Oak Lawn, Phoenix, Pittsburgh, Portland, Rochester, Sacramento, San Diego, San Francisco, Scottsdale, Seattle, Silver Spring, Springfield, St Louis, Stanford, Tallahassee, Thousand Oaks, Tulsa, Weston és Wichita (Egyesült Államok)Mind a 73 helyszín megnézéseMég 1 másik országban, 5 helyszínen
- Azonosító
- Állapot
- Fut, nem toboroz
- Résztvevők
- 103 fő vett részt
- Kezdés
- 2018. jún. 15.
- Várható befejezés
- 2028. jún.
- A vizsgálat típusa
- Beavatkozással járó, 5 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Tendyne Mitral Valve System
- MitraClip System
- A regiszteradat frissítve
- 2026. július 23.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 39 feltétel megnézéseKevesebb
Ki vehet részt
- Symptomatic, moderate-to-severe or severe mitral regurgitation (MR ≥ Grade III per American Society of Echocardiography criteria), or severe mitral annular calcification (MAC), where a transcatheter therapy is deemed more appropriate than open surgery by the local site heart team; Note: MR and MS severity must be determined by assessment of a qualifying transesophageal echocardiogram (TEE) and transthoracic echocardiogram (TTE), obtained within 120 days prior to subject consent, and must be confirmed by the Echocardiography Core Laboratory; Note: Patients with severe MAC must have symptomatic mitral valve disease associated with MR≥ Grade III, or severe mitral stenosis (MS), or both moderate MR and moderate MS as assessed by the Echocardiography Core Laboratory
- NYHA Functional Classification ≥ II (if Class IV, patient must be ambulatory)
- The local site heart team determines that the subject has been adequately treated per applicable standards for coronary artery disease (e.g., revascularization), left ventricular dysfunction (e.g., cardiac resynchronization therapy) and heart failure (e.g., GDMT). The SEC must concur that the subject has been adequately treated
- The local site heart team and the SEC concur on the intended study cohort for the subject; Randomized cohort: Eligibility for this cohort is limited to subjects where the local site heart team deems the mitral valve anatomy is suitable for TEER and are within approved Mitra Clip indications, which must be confirmed by experienced Mitra Clip operators within the SEC. Subjects with primary MR must be at prohibitive surgical risk, while subjects with secondary MR must be symptomatic despite maximally-tolerated guideline-directed medical therapy and meet the Mitra Clip Indications for Use; Non-repairable cohort: Eligibility for this cohort is limited to subjects where the local site heart team deems the mitral valve anatomy is not suitable for TEER with Mitra Clip or does not meet Mitra Clip indications, which must be confirmed by experienced Mitra Clip operators from the SEC; Severe MAC cohort: Eligibility for this cohort is limited to subjects where the local site heart team deems the degree of MAC renders the subject unsuitable for mitral valve surgery; Severe MAC CAP cohort: Eligibility for this cohort is identical to the original Severe MAC cohort
- Age 18 years or older at time of consent
- Subject has been informed of the nature of the trial and agrees to its provisions, including the possibility of randomization to the Control group, complying with trial required testing, medications, and follow-up visits, and has provided written informed consent
Ki nem vehet részt
- Prior surgical or interventional treatment of mitral valve involving implantation of prosthetic material (e.g. valve repair or replacement, or Mitra Clip)
- Any surgical or interventional procedure within the period of 60 days prior to or planned procedure 60 days following subject registration
- Implant or revision of CRT device within 90 days prior to intended subject registration
- Myocardial infarction within 30 days prior to intended subject registration
- CVA within 6 months prior to intended subject registration
- Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support devices at the time of planned implant procedure
- Subject has COPD requiring continuous home oxygen therapy or chronic outpatient oral steroid use
- Status 1 heart transplant or prior orthotopic heart transplantation
- Currently participating in an investigational drug or another device trial that has not reached its primary endpoint; Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials
- Chest condition that prevents transapical access
- Aortic valve disease requiring surgery or transcatheter intervention
- Tricuspid valve disease requiring surgery or transcatheter intervention
- Symptomatic, unresolved multi-vessel or unprotected left main coronary artery disease (e.g., active ischemia) requiring stenting or CABG
- Any of the following: leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy if cannot be adequately treated
- History of endocarditis within 6 months of planned implant procedure
- Active systemic infection requiring antibiotic therapy
- Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution, anti-coagulation or antiplatelet therapy) that cannot be adequately managed medically
- Known hypersensitivity to nickel or titanium
- Subject is undergoing hemodialysis due to chronic renal failure
- Subject has pulmonary arterial hypertension (fixed PAS >70mmHg). Note: If PAS > 70mmHg, site must provide documentation PAS is not fixed in order to be eligible
- Subjects with non-cardiac comorbidities that are likely to result in a life expectancy of less than 12 months
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
- LVEF less than 25% assessed by the site based on a TTE obtained within 120 days prior to subject consent; Note: LVEF will be principally based on TTE and confirmed by the Echocardiography Core Laboratory
- LVEDD > 7.0 cm assessed by the site based on a TTE obtained within 120 days prior to subject consent; Note: A qualifying LVEDD must be confirmed by the Echocardiography Core Laboratory
- Pregnant, lactating, or planning pregnancy during the clinical investigation follow-up period; Note: Female subjects of childbearing age should be instructed to use safe contraception (e.g. intrauterine devices, hormonal contraceptives: contraceptive pills, implants, transdermal patches hormonal vaginal devices, injections with prolonged release)
- Mitral valvular vegetation or mass
- Left Ventricle or Left Atrium thrombus
- Mitral pathoanatomy and LVOT anatomy deemed not suitable for Tendyne transcatheter mitral valve implantation
- Severe tricuspid regurgitation or severe right ventricular dysfunction
- Unresolved severe symptomatic carotid stenosis (> 70% by ultrasound)
- Hypertrophic or restrictive cardiomyopathy, or constrictive pericarditis
- Subjects in whom TEE is contraindicated or high risk
- Modified Rankin Scale ≥ 4 disability
Helyszínek itt: Egyesült Államok
Még 1 másik országban, 5 helyszínen
- Albany Medical College at Albany Medical CenterAlbany, Egyesült Államok
- University of Michigan Medical CenterAnn Arbor, Egyesült Államok
- Mission HealthAsheville, Egyesült Államok
- Emory University HospitalAtlanta, Egyesült Államok
- Piedmont Heart InstituteAtlanta, Egyesült Államok
- University of Colorado HospitalAurora, Egyesült Államok
- St. David's Healthcare Office of ResearchAustin, Egyesült Államok
- MedStar Union Memorial HospitalBalitmore, Egyesült Államok
- University of Maryland Medical CenterBaltimore, Egyesült Államok
- Northwell Health/South Shore University HospitalBay Shore, Egyesült Államok
- Baptist Medical Center PrincetonBirmingham, Egyesült Államok
- UAB University HospitalBirmingham, Egyesült Államok
- St. Alphonsus Regional Medical CenterBoise, Egyesült Államok
- Manatee Memorial HospitalBradenton, Egyesült Államok
- Buffalo General Medical CenterBuffalo, Egyesült Államok
- Medical University of South CarolinaCharleston, Egyesült Államok
- Atrium Health - Carolinas Medical CenterCharlotte, Egyesült Államok
- Novant Health Heart and Vascular Research InstituteCharlotte, Egyesült Államok
- University of Virginia Medical CenterCharlottesville, Egyesült Államok
- Rush University Medical CenterChicago, Egyesült Államok
- University of Cincinnati Medical CenterCincinnati, Egyesült Államok
- BayCare Healthcare System - Morton Plant HospitalClearwater, Egyesült Államok
- The Cleveland Clinic FoundationCleveland, Egyesült Államok
- Baylor Scott & White The Heart Hospital - DallasDallas, Egyesült Államok
- Medical City Dallas HospitalDallas, Egyesült Államok
- Delray Medical CenterDelray Beach, Egyesült Államok
- Henry Ford HealthDetroit, Egyesült Államok
- Inova Fairfax HospitalFalls Church, Egyesült Államok
- Fresno Heart HospitalFresno, Egyesült Államok
- HCA Florida north florida HospitalGainesville, Egyesült Államok
- University of FloridaGainesville, Egyesült Államok
- Hackensack University Medical CenterHackensack, Egyesült Államok
- UTHealth Memorial HermannHouston, Egyesült Államok
- Ascension St. VincentIndianapolis, Egyesült Államok
- Saint Luke's Hospital of Kansas CityKansas City, Egyesült Államok
- Baptist Health Medical CenterLittle Rock, Egyesült Államok
- Cedars-Sinai Medical CenterLos Angeles, Egyesült Államok
- University of Southern California University HospitalLos Angeles, Egyesült Államok
- Catholic Medical CenterManchester, Egyesült Államok
- Wellstar Kennestone Regional Medical CenterMarietta, Egyesült Államok
- Baptist Memorial HospitalMemphis, Egyesült Államok
- Baptist Hospital of MiamiMiami, Egyesült Államok
- Medical College of WisconsinMilwaukee, Egyesült Államok
- Abbott-Northwestern HospitalMinneapolis, Egyesült Államok
- The International Heart Institute of MontanaMissoula, Egyesült Államok
- West Virginia UniversityMorgantown, Egyesült Államok
- Ascension Saint ThomasNashville, Egyesült Államok
- TriStar Centennial Medical centerNashville, Egyesült Államok
- Robert Wood Johnson University HospitalNew Brunswick, Egyesült Államok
- Lenox Hill HospitalNew York, Egyesült Államok
- New York Presbyterian Hospital/Cornell UniversityNew York, Egyesült Államok
- Newark Beth Israel Medical CenterNewark, Egyesült Államok
- Advocate Christ Medical CenterOak Lawn, Egyesült Államok
- Banner University Medical CenterPhoenix, Egyesült Államok
- Allegheny General Hospital - ASRIPittsburgh, Egyesült Államok
- UPMC ShadysidePittsburgh, Egyesült Államok
- Providence Heart & Vascular InstitutePortland, Egyesült Államok
- Mayo ClinicRochester, Egyesült Államok
- Sutter Medical Center SacramentoSacramento, Egyesült Államok
- University of California, Davis Medical CenterSacramento, Egyesült Államok
- San Diego Cardiac CenterSan Diego, Egyesült Államok
- University of California at San FranciscoSan Francisco, Egyesült Államok
- Scottsdale Healthcare - SheaScottsdale, Egyesült Államok
- Swedish Medical Center - Heart & VascularSeattle, Egyesült Államok
- Adventist HealthCare White Oak Medical CenterSilver Spring, Egyesült Államok
- Prairie Education & Research CooperativeSpringfield, Egyesült Államok
- St. Louis University HospitalSt Louis, Egyesült Államok
- Stanford Health CareStanford, Egyesült Államok
- Tallahassee Research InstituteTallahassee, Egyesült Államok
- Los Robles Regional Medical CenterThousand Oaks, Egyesült Államok
- Oklahoma Heart Institute at UticaTulsa, Egyesült Államok
- Cleveland Clinic FloridaWeston, Egyesült Államok
- Ascension Via Christi Hospitals WichitaWichita, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Plan (MAC CAP). Subjects in the Randomized cohort were randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts were receive the trial device.
A teljes eredeti leírásKevesebb
The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) was to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification.
This randomized controlled trial would provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System would be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who were not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and were also not suitable for transcatheter repair with MitraClip, would be enrolled in the Non-repairable cohort.
Subjects would be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years.
A vizsgálat 5 csoportja
- Randomized Cohort - Treatment GroupA vizsgált kezelés
Treatment of mitral regurgitation with the Tendyne Transcatheter Mitral Valve System
Kezelés: Tendyne Mitral Valve System
- Randomized Cohort - Control GroupMár használt kezelés, összehasonlításként
Treatment of mitral regurgitation within commercially approved MitraClip system indications
Kezelés: MitraClip System
- Non-repairable CohortA vizsgált kezelés
Treatment of mitral regurgitation with the Tendyne Transcatheter Mitral Valve System
Kezelés: Tendyne Mitral Valve System
- Severe Mitral Annular Calcification (MAC) CohortA vizsgált kezelés
Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Transcatheter Mitral Valve System
Kezelés: Tendyne Mitral Valve System
- Severe Mitral Annular Calcification Continued Access Plan (MAC CAP) CohortA vizsgált kezelés
Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Transcatheter Mitral Valve System after the completion of enrollment in the Severe MAC Cohort
Kezelés: Tendyne Mitral Valve System
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2026. július 23.